Alumis (NASDAQ:ALMS) Receives “Buy” Rating from HC Wainwright

Alumis (NASDAQ:ALMS)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a report released on Monday,Benzinga reports. They currently have a $19.00 price objective on the stock. HC Wainwright’s price target indicates a potential upside of 313.94% from the stock’s current price.

Other analysts have also recently issued reports about the company. Oppenheimer assumed coverage on Alumis in a research report on Thursday, January 30th. They set an “outperform” rating and a $32.00 price objective on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Alumis in a research report on Thursday, November 14th. Seven equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, Alumis presently has an average rating of “Buy” and a consensus target price of $26.57.

Alumis Stock Up 1.1 %

Shares of NASDAQ ALMS opened at $4.59 on Monday. The business’s 50 day moving average is $6.58 and its two-hundred day moving average is $9.29. Alumis has a 12 month low of $4.36 and a 12 month high of $13.53.

Institutional Trading of Alumis

Several institutional investors have recently bought and sold shares of the stock. BNP Paribas Financial Markets acquired a new stake in Alumis in the 3rd quarter valued at $27,000. Wells Fargo & Company MN boosted its stake in Alumis by 77.1% in the 4th quarter. Wells Fargo & Company MN now owns 8,779 shares of the company’s stock valued at $69,000 after buying an additional 3,823 shares in the last quarter. Northern Trust Corp boosted its stake in Alumis by 4.3% in the 4th quarter. Northern Trust Corp now owns 111,326 shares of the company’s stock valued at $875,000 after buying an additional 4,587 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Alumis by 4.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 113,401 shares of the company’s stock valued at $891,000 after buying an additional 4,808 shares in the last quarter. Finally, Barclays PLC boosted its stake in Alumis by 33.9% in the 4th quarter. Barclays PLC now owns 24,581 shares of the company’s stock valued at $193,000 after buying an additional 6,221 shares in the last quarter.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.